公开(公告)号：US20230323344A1

公开(公告)日：2023-10-12

申请号：US17929956

申请日：2022-09-06

Applicant: ModernaTx, Inc.

Inventor： Gabor BUTORA ,  Andrew W. Fraley ,  Edward John Miracco ,  Jennifer Nelson ,  Amy Rhoden Smith ,  Matthew Stanton

IPC: C12N15/113 ,  C12N15/11

CPC classification number: C12N15/113 ,  C12N15/111 ,  C12N2310/317 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/351 ,  C12N2320/51

Abstract: The disclosure provides polynucleotides encoding a polypeptide including a morpholino linker. In some embodiments, the polynucleotides of the invention have increased stability compared to wild-type polynucleotides.

公开(公告)号：US11434486B2

公开(公告)日：2022-09-06

申请号：US15760667

申请日：2016-09-19

Applicant: ModernaTX, Inc.

Inventor： Gabor Butora ,  Andrew W. Fraley ,  Edward John Miracco ,  Jennifer Nelson ,  Amy Rhoden Smith ,  Matthew Stanton

IPC: A01N43/04 ,  A61K31/70 ,  C12N15/113 ,  C12N15/11

Abstract: The disclosure provides polynucleotides encoding a polypeptide including a morpholino linker. In some embodiments, the polynucleotides of the invention have increased stability compared to wild-type polynucleotides.

公开(公告)号：US12109274B2

公开(公告)日：2024-10-08

申请号：US15760686

申请日：2016-09-19

Applicant: ModernaTX, Inc.

Inventor： Gabor Butora ,  Andrew W. Fraley ,  Edward John Miracco ,  Jennifer Nelson ,  Amy Rhoden Smith ,  Matthew Stanton ,  Brian R. Fritz

IPC: A61K48/00 ,  C07F9/6558 ,  C07F9/6561 ,  C07H21/02 ,  C12N15/67

CPC classification number: A61K48/0066 ,  C07F9/65586 ,  C07F9/65616 ,  C07H21/02 ,  C12N15/67

Abstract: The invention features polynucleotides encoding a polypeptide including a 3′-stabilizing region and having increased stability compared to wild-type polynucleotides.

公开(公告)号：US11202793B2

公开(公告)日：2021-12-21

申请号：US16333330

申请日：2017-09-14

Applicant: ModernaTX, Inc.

Inventor： Stephen Hoge ,  William Issa ,  Edward J. Miracco ,  Jennifer Nelson ,  Amy E. Rabideau ,  Gabor Butora

IPC: A61K31/7105 ,  C07K14/505 ,  C12P19/34 ,  A61P33/00 ,  A61P31/12 ,  A61P31/04 ,  A61P35/00 ,  C12N15/10 ,  G01N33/68

Abstract: The invention relates to improved RNA compositions for use in therapeutic applications. The RNA compositions are particularly suited for use in human therapeutic application (e.g., in RNA therapeutics). The RNA compositions are made by improved processes, in particular, improved in vitro-transcription (IVT) processes. The invention also relates to methods for producing and purifying RNA (e.g, therapeutic RNAs), as well as methods for using the RNA compositions and therapeutic applications thereof.

公开(公告)号：US10653712B2

公开(公告)日：2020-05-19

申请号：US16001786

申请日：2018-06-06

Applicant: ModernaTX, Inc.

Inventor： Stephen Hoge ,  William Issa ,  Edward J. Miracco ,  Jennifer Nelson ,  Amy E. Rabideau ,  Gabor Butora

IPC: C12P19/34 ,  A61K31/7105 ,  C07K14/505 ,  A61P33/00 ,  A61P31/12 ,  A61P31/04 ,  A61P35/00 ,  C12N15/10 ,  G01N33/68

Abstract: The invention relates to improved RNA compositions for use in therapeutic applications. The RNA compositions are particularly suited for use in human therapeutic application (e.g., in RNA therapeutics). The RNA compositions are made by improved processes, in particular, improved in vitro-transcription (IVT) processes. The invention also relates to methods for producing and purifying RNA (e.g, therapeutic RNAs), as well as methods for using the RNA compositions and therapeutic applications thereof.

公开(公告)号：US09751925B2

公开(公告)日：2017-09-05

申请号：US14960031

申请日：2015-12-04

Applicant: ModernaTX, Inc.

Inventor： Stephen G. Hoge ,  William Joseph Issa ,  Edward John Miracco ,  Jennifer Nelson ,  John Reynders ,  Matthew Stanton

IPC: C07K14/535 ,  C12P19/34 ,  C07K14/505 ,  C12N9/00 ,  C12N9/02

CPC classification number: C07K14/535 ,  A61K48/005 ,  C07K14/505 ,  C12N9/0069 ,  C12P19/34 ,  C12P21/02 ,  C12Y113/12007

Abstract: The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.